What is the status of Empliciti® (elotuzumab), the new immunotherapy?

 

In this week’s video, Dr. Brian G.M. Durie explains the recent FDA approval for the use of elotuzumab, pomalidomide, and dexamethasone (EPd) for the treatment of relapsed or refractory myeloma in patients who have received at least two prior therapies.

BOTTOM LINE:
An important new combination – EPd – is now approved and available.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org